Propranolol: What is BLOCKing its clinical investigation in breast cancer?

Research output: Contribution to journalArticlepeer-review

Abstract

Presurgical propranolol modulates biomarkers associated with breast cancer progression. β-adrenergic signaling promotes invasion, epithelial-to-mesenchymal transition phenotype, and immune cell infiltration into the tumor microenvironment. Blockade of the β-adrenergic receptor signaling with propranolol, along with potential future combinatorial strategies, holds promise for reducing breast cancer progression and metastasis.

Original languageEnglish (US)
Pages (from-to)1781-1783
Number of pages3
JournalClinical Cancer Research
Volume26
Issue number8
DOIs
StatePublished - Apr 15 2020

Bibliographical note

Publisher Copyright:
© 2020 American Association for Cancer Research.

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Comment

Fingerprint

Dive into the research topics of 'Propranolol: What is BLOCKing its clinical investigation in breast cancer?'. Together they form a unique fingerprint.

Cite this